Chiusura precedente | 778,50 |
Aperto | 791,00 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 791,00 - 810,50 |
Intervallo di 52 settimane | 791,00 - 810,50 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 120,703M |
Beta (5 anni mensile) | 1,54 |
Rapporto PE (ttm) | 1,09 |
EPS (ttm) | 7,55 |
Prossima data utili | N/D |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
ANNOUNCEMENT NO. 233 14 December 2022 Management change Steen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S. It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023. The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 20
ANNOUNCEMENT NO. 232 Trading statement for Q1 2022/23 (1 July - 30 September 2022) Good start to the fiscal year with 34% revenue growth The financial year 2022/23 is off to a good start with revenue up 34% in the first quarter to DKK 113.8 million from DKK 85.0 million in the year-earlier period. While all product segments recorded growth, the North American market remains the main geographical growth driver. EBITDA amounted to DKK 65.2 million, a year-on-year increase of 50%, for an EBITDA mar
ANNOUNCEMENT NO. 229 15 September 2022 Annual Report 2021/22 (1 July 2021 - 30 June 2022) Strong growth despite challenging conditions ChemoMetec grew its revenue by 52% in 2021/22 from DKK 281.1 million to DKK 427.2 million despite the extraordinary market conditions caused by Covid-19 and the war in Ukraine, including supply chain shortages. As a result, EBITDA grew from DKK 135.6 million to DKK 222.9 million, a 64% increase. As in previous years, growth was primarily driven by increasing sale